Skip to main content

Prednisone tapering in RA

Presenter: Gerd-Rüdiger Burmester, Charité-Universitätsmedizin Berlin, Germany.

Wednesday 12 June: 16:15–17:45 (Abstract OP0030)

Rheumatoid arthritis patients who had stable low disease activity on tocilizumab plus conventional DMARDs and prednisone were randomly assigned to taper their prednisone dose or continue with the same dose in this 24-week study. The primary outcome is change in DAS28-ESR from baseline to week 24.

More on this trial